TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05010174
Drug: MDR product
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observation of patients previously receiving MDR product(s)
Study: NCT06203405
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous intravenous infusion of fentanyl 25-75 micrograms/hour
Study: NCT05066841
Drug: 10% CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang) and 90% starch for 12 weeks
Study: NCT06085898
Drug: Stryphnodendron Adstringens 3% - once daily post bath
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intimate Soap
Study: NCT00000826
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05789732
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo treatment once daily.
Study: NCT05075876
Drug: SP-01 manufactured by Site K (SP-01-K, Transdermal patch contained granisetron)
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single application for 6 days
Study: NCT05600218
Drug: No intervention - Observational study
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real life drug evaluation
Study: NCT04075435
Drug: high CBD/low THC sublingual solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemp derived solution to be administered sublingually twice daily.
Study: NCT05966025
Drug: conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: will taken by patient in control group
Study: NCT06023095
Drug: LY3502970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06023095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05421078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active ingredient
Study: NCT04616781
Drug: Isocaloric dextrose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drink indistinguishable from ketone ester
Study: NCT05728892
Drug: Melatonin 3 MG
Normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preopertive melatonin adminstration oral 0.2 mg /kg 45 min before general anaethesia.
Study: NCT05626881
Drug: sylimarin cream
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin was manufactured with concentration of 1.4%
Study: NCT04871334
Drug: TWP-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion Q2W for 4 weeks (28-day cycles)
Study: NCT04844385
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m2, bid, d1-14, q3w during radiotherapy
Study: NCT06165068
Drug: Aspirin 81Mg Ec Tab
Normalized name: ASPIRIN 81MG EC TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients take aspirin 81 mg per day.
Study: NCT05066620
Drug: Chinese herbal medicine FYTF-919
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml \* Q6H will be given through nasal feeding)
Study: NCT06534021
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be given one dose of placebo. Subjects should avoid strenuous exercise within 48 h before administration and remain seated or semi-recumbent (except for necessary activities) for 4 h after administration. IASO-782 solution for injection or placebo was diluted in 0.9% sodium chloride injection (corresponding to the dose administered according to the body weight at baseline and the dose group) with a total volume of 250 mL, administered as a single intravenous drip at a drip rate recommended by the drug manual on the day of administration, The infusion time is about 90 minutes (± 15 minutes).
Study: NCT06485271
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment
Study: NCT05086692
Drug: MDNA11
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDNA11 will be administered, IV on a once every 2 weeks (Q2W) dosing schedule. Provisional dose cohorts for monotherapy dose escalation doses ranging from 0.003 to 0.6 (mg/kg): until determining the monotherapy Recommended Dose for Expansion (mRDE).
Study: NCT06663943
Drug: CM313 (SC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM313 is an anti-CD38 monoclonal antibody that can help pemphigus patients systematically treat rapid glucocorticoid reduction. It has been proven to have good safety in non-clinical studies and is suitable for human studies
Study: NCT06663943
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the control group receive azathioprine in combination with steroid therapy.
Study: NCT05667298
Drug: Adjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~1. Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~2. Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~3. Standard of Care Arm (CROSS):~4. Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible.
Study: NCT06292585
Drug: Medical therapy alone
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the best conservative treatment recommended by the guidelines, and conservative treatment will be the same in both groups. Conservative treatment includes medication and general treatment. Drug therapy can be divided into hemostatic treatment, antihypertensive treatment, and symptomatic treatment. Specific local clinical diagnosis and treatment standards shall prevail or refer to corresponding clinical guidelines.
Study: NCT05832034
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusions, containing sodium chloride 0.9%, at baseline and after 4 and 8 weeks.
Study: NCT06005259
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone 25 mg capsule
Study: NCT06005259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT04926753
Drug: 5-Fluorouracil, Cisplatin, Toripalimab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: FP combined with Toripalimab Combination drugs: 5-Fluorouracil(F), Cisplatin/Carboplatin(P) and Toripalimab every 21 days for 2 cycles This is a single-arm study with all patients receiving these three drugs.
Study: NCT05827497
Drug: Methotrexate 25mg
Normalized name: METHOTREXATE 25MG/ML/NACL 0.49% INJ
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25mg daily
Study: NCT05305365
Drug: QBS72S
Approvals — FDA: no, EMA: no, PMDA: no
Description: QBS72S 18mg/m2 injection given intravenous once a month.
Study: NCT06583291
Drug: Allogeneic dopaminergic neural precursor cell(iDAP)
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral implantation
Study: NCT06583551
Drug: Myorel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacarbamol (380mg), paracetamol (300mg)
Study: NCT06583811
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: to compare remifentanil and remimazolam to limit patient movement during long-eye surgeries under local anesthesia.
Study: NCT05030142
Drug: Best medical treatment alone
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical treatment alone (usual care)
Study: NCT04953923
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule for oral administration
Study: NCT05511350
Drug: TJ210001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05645627
Drug: IBI112
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
Study: NCT05645627
Drug: placebo /IBI112
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo by subcutaneous injection cross over IBI112 by subcutaneous injection at week 16 through week 48
Study: NCT06440772
Drug: Ringer's Lactate Crystalloid Solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 ml/kg ml of Ringer's Lactate is given in 10 min amongst initially tolerant fluid responders.
Study: NCT05851560
Drug: Oxidized regenerated cellulose(ORC)
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigate the antiadhesive effect of multiple antiadhesive barriers in thyroid surgery
Study: NCT06109428
Drug: HTX-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg
Study: NCT06109428
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg
Study: NCT06109428
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g
Study: NCT05449028
Drug: H. pylori eradication scheme A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 8/8h, for 14 days
Study: NCT05449028
Drug: H. pylori eradication scheme B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h, for 14 days
Study: NCT05449028
Drug: H. pylori eradication scheme C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40mg bid + bismuth subsalicylate 420mg 6/6h + metronidazole 375mg 6/6h + tetracycline 375mg 6/6h, for 10 days
Study: NCT05449028
Drug: H. pylori eradication scheme E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
Study: NCT06341127
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluoxetine daily, 2.5 to 5 mg.
Study: NCT06587347
Drug: Standard medical treatment (SMT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive standard antiplatelet therapy.
Study: NCT06663605
Drug: PALI-2108
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose
Study: NCT06663605
Drug: PALI-2108 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose
Study: NCT06615570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension for oral administration.
Study: NCT05212259
Drug: Collagen type II (40 mg/day)
Normalized name: collagen type II
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules per day
Study: NCT05212259
Drug: Collagen type II (80mg/day)
Normalized name: collagen type II
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules per day
Study: NCT05212259
Drug: Collagen type II (120 mg/day)
Normalized name: collagen type II
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules per day
Study: NCT05212259
Drug: Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules per day
Study: NCT05212259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules per day
Study: NCT06504030
Drug: modified-DEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: For non-EBV-HLH patients: Liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed.~For EBV-HLH patients: PD-1 monoclonal antibody, 2 mg/kg (maximum dose, 200 mg) d-3, liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed.
Study: NCT06193538
Drug: Recombinant NV-A01 adenovirus injection
Normalized name: adenovirus, type 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with advanced glioblastoma were intratumoral injected with NV-A01. Or the NV-A01 was injected after tumor resection.
Study: NCT05101187
Drug: AmBisome®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial course of at least 10 days of AmBisome® administered daily at a dose of 3 mg/kg by IV infusion over a 30- to 60-minute period or according to local guidelines Administration of SOC will follow international, national, or local guidelines and product labelling.
Study: NCT01142414
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05448001
Drug: JP-1366 20mg
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: JP-1366 20 mg 1 capsule, Lansoprazole 30 mg placebo 1 capsule before meal
Study: NCT00018109
Drug: creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03160430
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo capsule
Study: NCT06481995
Drug: Fibrogammin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrogammin is administered according to the Summary of product characteristics (SmPC) after measured blood loss exceeds 700 ml and bleeding is ongoing
Study: NCT02001584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05575999
Drug: Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: The plan will be to stratify patients in two groups: intervention group receiving 20 cc combination of BKK (Bupivacaine HCl 60 mg \[3 mg/mL\], Ketorolac Tromethamine 24 mg \[1.2mg/mL\], Ketamine HCl 24 mg \[1.2 mg/mL\]) vs the control group receiving 20 cc of 0.5% bupivacaine (Bupivacaine HCL 100 mg \[5mg/ml\]. The dose can be repeated multiple times during the procedure as per operator's discretion. The patients will be further stratified into sub-groups based on type of procedure they had undergone. Analgesia/anesthesia strategy will be local infiltration of the drug along with a sedating agent based on institutional standard of care. The dose of the medicines will be adjusted as per discretion of the operator to maintain adequate anesthesia/analgesia during and after the procedure.
Study: NCT06158737
Drug: JS010 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study adopts a dose escalation design with six preset dose levels, namely 3mg, 30mg, 150mg, 300mg,600mg, 900mg, single subcutaneous injection. A total of 48 healthy subjects were enrolled in the experiment, 8 in each group.They were randomly assigned to receive JS010 injection and matching placebo in a ratio of 3:1. In accordance with the dose-escalation principle,Starting from the lowest initial dose, increasing to the higher dose and proceeding in sequence. Each subject can receive only one dose Level of single subcutaneous administration.
Study: NCT06158737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study adopts a dose escalation design with six preset dose levels, namely 3mg, 30mg, 150mg, 300mg,600mg, 900mg, single subcutaneous injection. A total of 48 healthy subjects were enrolled in the experiment, 8 in each group.They were randomly assigned to receive JS010 injection and matching placebo in a ratio of 3:1. In accordance with the dose-escalation principle,Starting from the lowest initial dose, increasing to the higher dose and proceeding in sequence. Each subject can receive only one dose Level of single subcutaneous administration.
Study: NCT06573411
Drug: ACEI/ARB+ Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control patients will be administered maximum tolerable dose of ACEI/ARB and a placebo.
Study: NCT04862091
Drug: ZYTIGA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZYTIGA®
Study: NCT05597020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching daridorexant is provided as identical-looking oral tablets, formulated with the same inactive ingredients (excipients) as the active tablets.
Study: NCT06573164
Drug: conventional medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use conventional medication as needed based on the patient's condition.
Study: NCT06574347
Drug: PLB1004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive PLB1004 80mg orally once per day (QD).
Study: NCT05438082
Drug: Antibiotic Prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: This trial will contain two arms in which patients will be randomized to receive one dose of either Trimethoprim (if \< 2 months) or Trimethoprim-Sulfamethoxazole (if ≥ 2 months) or placebo in suspension. Dosing regimen for the active treatment (Trimethoprim) will be based on weight (5mg/kg of Trimethoprim component) with a maximum dosage of 320mg
Study: NCT05397379
Drug: HEC96719
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT05397379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator
Study: NCT03759093
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
Study: NCT03759093
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosing in a range of 100, 300, 500 mg PO on Day 1, 8, 15, 22 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
Study: NCT06271551
Drug: Active Comparator: Androgen deprivation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants (n=155) receiving solely androgen deprivation therapy for 12 months.
Study: NCT05690737
Drug: Standard prophylactic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants assigned to the control group will follow the collaborated neurologist's recommendation, to take the prophylactic medication. The Multidisciplinary Panel on Neuropathic Pain (MPNP) of Hong Kong has published the treatment algorithm for migraine, which is in line with the guideline of the Scottish Intercollegiate Guidelines Network (SIGN) on the pharmacological management of migraine (SIGN 155). Beta-blockers, specifically metoprolol and propranolol, are one of the first-line treatments for migraine prophylaxis. The dosage will start on 10mg and slowly increase by 10mg every week until the dosage reached the highest dose of 150mg/day. The whole course will last for 48 weeks. The second line drug such as amitriptyline and the third line drug such as gabapentin will be adopted according to doctor's judgement if necessary. RA will help the participants to make appointment with the neurological doctor, to obtain the prescription. The adverse events will be recorded accordingly.
Study: NCT05809895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline intravenously (IV) Q3W
Study: NCT05932316
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo inhalation prior to repeating spirometry
Study: NCT05384847
Drug: Thyroid hormone T3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be admitted to the General Clinical Research Center (GCRC) for up to 5 days and will receive study medication twice a day. Participants will receive oral T3 under the supervision of the Principal Investigator or qualified co-investigators at the GCRC. The study drug will be given within 30 days after enrollment.
Study: NCT05898087
Drug: Marcaine 0.25 % Injectable Solution
Normalized name: Marcaine 0.25 % Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this arm will receive an injection of 20cc of injectable 0.25% bupivacaine solution. It will be injected in a fan-like pattern beneath the pectoralis fascia
Study: NCT05898399
Drug: ART6043
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART6043 will be given orally.
Study: NCT05074433
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06041477
Drug: Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial infusion chemotherapy with (oxaliplatin 135mg/m2 over 3hrs, calcium folinic acid 400mg/m2 or levofolinic acid 200mg/ m2 over 1.5hrs, 5-FU 400mg/m2 over 2hrs, 5-FU 2400mg/m2 over 46hrs,every 4 weeks)
Study: NCT06467318
Drug: NSAID, Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants post mechanical pleurodesis on pneumothorax will be divided into two groups: Group A: patients taking classic pain management with NSAID. Group B: patients taking classic pain management without NSAID.
Study: NCT06081166
Drug: Rosuvastatin Calcium
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 40 mg
Study: NCT06408285
Drug: TQC3927 powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQC3927 is a targeted inhibitor.
Study: NCT06408285
Drug: TQC3927 powder for inhalation placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQC3927 powder for inhalation placebo contains no active substance.
Study: NCT06211647
Drug: [177Lu]Lu-XT117
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[177Lu\]Lu-XT117 is a radiopharmaceutical therapy in which an beta emitter, Lu-177, is conjugated to XT117. Patients will receive \[177Lu\]Lu-XT117 administration at fixed dose levels at an interval of 6 weeks between each dose.
Study: NCT01070290
Drug: Oxaliplatin, capecitabine or irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice or oxaliplatin, capecitabine or irinotecan
Study: NCT05050188
Drug: H008 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water
Study: NCT05251233
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules contain pharmaceutical-grade lactose monohydrate NF, a naturally occurring disaccharide of galactose bound to glucose.
Study: NCT04630158
Drug: SAF312
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular, suspension eye drops